Summary
Danaher Corporation's (DHR) Q1 2017 report highlights solid overall sales growth driven by strong performance in high-growth markets and acquisitions, despite a negative impact from currency exchange rates. The company experienced a total sales increase of 7.0% compared to the prior year, with existing businesses growing by 2.5% and acquisitions contributing 6.0%. While operating profit margins saw a slight decrease year-over-year due to investments in growth and integration costs from recent acquisitions like Cepheid, the underlying operational performance remains robust. Key segments like Life Sciences and Diagnostics demonstrated positive sales growth, with Diagnostics showing a significant 17.0% increase largely due to acquisitions. The company continues to focus on innovation, cost efficiency through the Danaher Business System, and strategic expansion in high-growth regions. Despite some headwinds from currency fluctuations and integration expenses, Danaher's diversified business model and strategic investments position it for continued growth, with management expressing confidence in its liquidity and ability to fund future operations and acquisitions.
Financial Highlights
52 data points| Revenue | $4.21B |
| Cost of Revenue | $1.87B |
| Gross Profit | $2.33B |
| R&D Expenses | $267.40M |
| SG&A Expenses | $1.45B |
| Operating Income | $617.00M |
| Interest Expense | $40.30M |
| Net Income | $506.10M |
| EPS (Basic) | $0.73 |
| EPS (Diluted) | $0.72 |
| Shares Outstanding (Basic) | 694.30M |
| Shares Outstanding (Diluted) | 705.70M |
Key Highlights
- 1Total sales increased by 7.0% to $4,205.7 million in Q1 2017 compared to $3,924.1 million in Q1 2016.
- 2Sales from existing businesses grew by 2.5%, indicating underlying organic growth, while acquisitions contributed an additional 6.0% to sales.
- 3High-growth markets led geographic sales growth, increasing at a mid-single digit rate, and represented approximately 28% of total sales.
- 4The Diagnostics segment saw significant sales growth of 17.0%, largely driven by the acquisition of Cepheid in late 2016.
- 5Operating profit margins slightly decreased from 15.6% in Q1 2016 to 14.8% in Q1 2017, attributed to growth investments and acquisition-related dilution.
- 6The company's effective tax rate decreased to 17.3% in Q1 2017 from 25.2% in Q1 2016, primarily due to lower foreign tax rates and discrete tax benefits.
- 7Operating cash flow from continuing operations decreased by 8% to $560.2 million, mainly due to higher income tax payments and working capital fluctuations.